Ding NL, Zhang F, Tang FS. Magnesium isoglycyrrhizinate in perioperative hepatic function protection: Insights from a clinical pharmacy perspective. World J Gastroenterol 2026; 32(41): 123866 [DOI: 10.3748/wjg.123866]
Corresponding Author of This Article
Fu-Shan Tang, PhD, Professor, Department of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, No. 6 Xuefu West Road, Xinpu New District, Zunyi 563006, Guizhou Province, China. fstang@vip.163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
letter
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Nov 7, 2026; 32(41): 123866 Published online Nov 7, 2026. doi: 10.3748/wjg.123866
Magnesium isoglycyrrhizinate in perioperative hepatic function protection: Insights from a clinical pharmacy perspective
Nan-Lan Ding, Feng Zhang, Fu-Shan Tang
Nan-Lan Ding, Feng Zhang, Fu-Shan Tang, Department of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, Zunyi 563006, Guizhou Province, China
Author contributions: Ding NL drafted and revised the manuscript; Zhang F provided discussion and literature support; Tang FS contributed to idea generation, revised the manuscript, and provided supervision; all authors reviewed and approved the final manuscript.
AI contribution statement: Portions of this manuscript were edited using AI tools solely for language refinement.
Conflict-of-interest statement: The authors declare no conflicts of interest. No financial support, commercial funding, consultancy fees, stock ownership, patents or other economic interests related to this work have been received by any author that could bias the research outcomes.
Corresponding author: Fu-Shan Tang, PhD, Professor, Department of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, No. 6 Xuefu West Road, Xinpu New District, Zunyi 563006, Guizhou Province, China. fstang@vip.163.com
Received: June 1, 2026 Revised: July 19, 2026 Accepted: July 27, 2026 Published online: November 7, 2026 Processing time: 107 Days and 8.3 Hours
Abstract
This letter to the editor reviews a study published in the World Journal of Gastroenterology that evaluated the efficacy of magnesium isoglycyrrhizinate (MgIG) in protecting liver function during the perioperative period following hepatectomy. The study demonstrated that perioperative administration of MgIG (both preoperatively for prevention and postoperatively) significantly reduced the incidence of postoperative liver injury, suppressed transaminase elevation, and accelerated liver function recovery. Building on these findings, we analyze relevant issues from a clinical pharmacy perspective, including the importance of patient stratification, the necessity of safety monitoring during treatment, pharmacokinetic mechanisms, and pharmacoeconomic implications. Finally, the article emphasizes that future research should further optimize patient selection criteria, enhance safety monitoring data, investigate pharmacological mechanisms, and conduct cost-effectiveness analyses to standardize and optimize the clinical use of MgIG in hepatectomy.
Core Tip: This letter to the editor reviews a recent study demonstrating that perioperative administration of magnesium isoglycyrrhizinate (MgIG) can mitigate postoperative liver injury and accelerate hepatic function recovery following hepatectomy. We emphasize the necessity of implementing measures, including risk-stratified patient selection, safety monitoring, pharmacotherapy management, mechanism investigation, and pharmacoeconomic evaluation, to standardize and optimize the clinical application of MgIG during hepatectomy.
